HSP90AA1 and Miyoshi myopathy: Taken together, our results provide the rationale for a novel treatment strategy combining selective HSP90α/β inhibitor and RAS-RAF-MEK-ERK signaling pathway inhibitors to improve patient outcome in RAS-mutated MM.